To summarize, our data suggest that ficolins may be considered candidate supplementary biomarkers of AML: low ficolin-1 as well as high ficolin-2 and ficolin-3 seem to be associated with that disease and differentiate patients not only from healthy controls but also from persons suffering from some other haematological malignancies (at least two groups of cancers: multiple myeloma and lymphoma). Here, FCN2 is linked to plasma cell myeloma.